Clinically, HISLA expression in TAMs was significantly correlated with therapeutic response and overall survival among breast cancer patients, indicating that HISLA is a potential prognostic biomarker and a valuable adjunct for guiding therapeutic decision-making. This evidence concerns the gene HISLA and breast carcinoma.